CRISM Therapeutics (LON:CRTX) Posts Earnings Results

CRISM Therapeutics (LON:CRTX) issued its earnings results on Monday. The company reported GBX (2.60) earnings per share for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Stock Up 1.5%

Shares of CRISM Therapeutics stock opened at GBX 9.90 on Tuesday. The firm has a market capitalization of £7.84 million, a P/E ratio of -1.94 and a beta of 0.58. CRISM Therapeutics has a 52 week low of GBX 8 and a 52 week high of GBX 18.50. The firm’s 50 day moving average is GBX 10.43 and its two-hundred day moving average is GBX 11.14.

CRISM Therapeutics Company Profile

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.